Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients. | ClinicalTrials HQ

Ask about research services

Swipe the table sideways for more columns.

Trial	Conditions	Status	Phase	Updated	More info	NCT ID
Trientine Tetrahydrochloride Administered Once a Day for the First Line Treatment of Wilson's Disease Patients.	Brain Diseases, Metabolic, Brain Diseases, Metabolic, Inborn, Congenital, Hereditary, and Neonatal Diseases and Abnormalities, Digestive System Diseases, Nutritional and Metabolic Diseases, Wilson disease, basal ganglia disorder, brain disorder, central nervous system disorder, hereditary disease, inborn errors of metabolism, inborn metal metabolism disorder, inherited neurodegenerative disorder, liver disorder, metabolic disease, movement disorder, nervous system disorder, neurodegenerative disease	Recruiting	Phase 3	2026-10-02		NCT07465718

1 results · Page 1 of 1

Swipe the table sideways for more columns.

Organizations	Linked trials
Orphalan	2

10 results · Page 1 of 1

Swipe the table sideways for more columns.

Research sites	City	Country	Linked trials
Beijing Friendship Hospital,Capital Medical University	Beijing	China	3
Beijing YouAn Hospital, Capital Medical University	Beijing	China	1
Children's Hospital & Institute of Child Health	Lahore	Pakistan	1
King Faisal Specialist Hospital and Research Center	Riyadh	Saudi Arabia	6
PIMS Hospital	Islamabad	Pakistan	1
Shifa International Hospital	Islamabad	Pakistan	3
The Second Affiliated Hospital Zhejiang University School of Medicine	Hangzhou	China	1
University of Colorado Anschutz School of Medicine	Denver	United States	1
University of Michigan Medical Centre	Ann Arbor	United States	1
Yale University School of Medicine	New Haven	United States	17